Mark Alvino Sells 13,500 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Mark Alvino sold 13,500 shares of Abeona Therapeutics stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $5.23, for a total value of $70,605.00. Following the transaction, the director directly owned 48,752 shares in the company, valued at $254,972.96. The trade was a 21.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Mark Alvino also recently made the following trade(s):

• On Thursday, November 13th, Mark Alvino sold 15,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $4.74, for a total value of $71,100.00.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $5.36 on Friday. The business has a 50-day moving average of $5.07 and a 200-day moving average of $5.64. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The company has a market capitalization of $290.46 million, a price-to-earnings ratio of 4.36 and a beta of 1.12. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, equities research analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, October 13th. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Hedge Funds Weigh In On Abeona Therapeutics

A number of institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Abeona Therapeutics by 14.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after purchasing an additional 381,357 shares in the last quarter. Vanguard Group Inc. increased its stake in Abeona Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock valued at $13,743,000 after purchasing an additional 95,878 shares in the last quarter. Boone Capital Management LLC acquired a new position in Abeona Therapeutics during the second quarter worth $7,126,000. Geode Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 129.1% in the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after buying an additional 623,243 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 56.4% in the third quarter. Kennedy Capital Management LLC now owns 1,050,863 shares of the biopharmaceutical company’s stock valued at $5,549,000 after buying an additional 378,860 shares in the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.